Skip to main content
Fig. 10 | BMC Biotechnology

Fig. 10

From: High-level expression of a novel liver-targeting fusion interferon with preferred Escherichia coli codon preference and its anti-hepatitis B virus activity in vivo

Fig. 10

Distribution of IFN α2b and IFN-CSP in liver (a), heart (b), spleen (c), lung (d), kidney (e) after a single i.v. administration of free IFN α2b or IFN-CSP in mice at 30, 60, 120, 240 and 480 min post-injection. Each point represents the mean ± SEM (n = 6). The ** and * indicate statistically significant differences of p <0.01 and p <0.05, respectively between IFN α2b and IFN-CSP treatments

Back to article page

BMC Biotechnology

ISSN: 1472-6750

Contact us